Accordingly, SLC7A5 has emerged as a promising novel strategy for cancer therapy and to control inflammatory and immunological disorders such as psoriasis, rheumatoid arthritis, or allergic diseases (Cibrian et al, 2020; Hayashi et al, 2020; Oda et al, 2010; Ogbechi et al, 2023; Owada et al, 2022). This evidence concerns the gene SLC7A5 and allergic disease.